The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the.
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square. For full details and to register, visit NCCN.org/hem.
Arix Bioscience PLC: Autolus provides business outlook for 2021 and 2022
DJ Autolus provides business outlook for 2021 and 2022
Arix Bioscience PLC (ARIX)
Autolus provides business outlook for 2021 and 2022
06-Jan-2021 / 10:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement. Arix Bioscience plc Autolus provides business outlook for 2021 and 2022 LONDON, 06 January 2021: Arix Bioscience plc ( Arix , LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Autolus Therapeutics ( Autolus , Nasdaq: AUTL), today announced a business outlook for 2021 and 2022.
The announcement can be accessed on the Autolus website at